Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C

Poynard, Thierry; Imbert-Bismut, Françoise; Munteanu, Mona; Messous, Djamila; Myers, Robert P; Thabut, Dominique; Ratziu, Vlad; Mercadier, Anne; Benhamou, Yves; Hainque, Bernard

doi:10.1186/1476-5926-3-8

Table 1 Summary of the diagnostic value of FibroTest for the staging of hepatic fibrosis and comparisons with hyaluronic acid, the Forns Index and the APRI Index in patients with chronic hepatitis C, from the published studies.

From: Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C

First author	N*	Methodology	Marker	Stage/Prevalence	AUROC SE	Cut off	Sensitivity	Specificity
Imbert-Bismut, 2001	189	Prospective Single center First year cohort	FibroTest	F2F3F4 / 0.38	0.84 (0.03)	0.10 0.30 0.60 0.80	0.97 0.79 0.51 0.29	0.24 0.65 0.94 0.95
Imbert-Bismut, 2001	134	Prospective Single center Validation cohort	FibroTest	F2F3F4 / 0.45	0.87 (0.03)	0.10 0.30 0.60 0.80	1.00 0.87 0.70 0.38	0.22 0.59 0.95 0.97
Poynard, 2001	165	Retrospective Randomized trial Multicenter	FibroTest	F3F4 Knodell / 0.32	0.74 (0.03)	0.10 0.30 0.60 0.80	0.96 0.81 0.50 0.13	0.24 0.65 0.92 0.98
Poynard, 2001	165	Retrospective Randomized trial Multicenter	Hyaluronic	F3F4 Knodell / 0.32	0.65 (0.03)	20 40 100	0.81 0.47 0.23	0.39 0.65 0.91
Poynard, 2003	352	Retrospective Randomized trial Multicenter Before treatment	FibroTest	F2F3F4 / 0.39	0.73 (0.03)	0.10 0.30 0.60 0.80	0.97 0.86 0.50 0.20	0.08 0.45 0.79 0.95
Poynard, 2003	352	Retrospective Randomized trial Multicenter After treatment	FibroTest	F2F3F4 / 0.32	0.77 (0.03)	0.10 0.30 0.60 0.80	0.98 0.85 0.46 0.16	0.15 0.39 0.81 0.97
Rossi, 2003	125	Prospective Multicenter Non-validated analyzers	FibroTest	F2F3F4 / 0.38	0.74 (0.05)	0.10 0.30 0.60 0.80	0.92 0.75 0.42 0.22	0.29 0.61 0.94 0.96
Myers, 2003	130	Retrospective Single center HCV-HIV Co-infection	FibroTest	F2F3F4 / 0.45	0.86 (0.04)	0.10 0.30 0.60 0.80	0.98 0.90 0.66 0.34	0.17 0.60 0.92 0.96
Thabut, 2003	249	Retrospective Single center From Imbert-Bismut, 2001	FibroTest	F2F3F4 / 0.38	0.84 (0.02)	0.10 0.30 0.60 0.80	0.98 0.84 0.58 0.29	0.22 0.65 0.93 0.95
Thabut, 2003	249	Retrospective Single center From Imbert-Bismut, 2001	Forns Index	F2F3F4 / 0.38	0.78 (0.03)	1 3 6 8	1.00 1.00 0.55 0.19	0.04 0.26 0.86 0.97
Le Calvez, 2004	323	Retrospective Single center From Imbert-Bismut, 2001	FibroTest	F2F3F4 / 0.41	0.83 (0.02)	0.10 0.30 0.60 0.80	0.97 0.81 0.58 0.33	0.30 0.66 0.93 0.95
Le Calvez, 2004	323	Retrospective Single center From Imbert-Bismut, 2001	APRI Index	F2F3F4 / 0.41	0.74 (0.03)	0.50 1.00 1.50 2.00	0.81 0.54 0.36 0.24	0.56 0.84 0.91 0.95
Callewaert, 2004	82	Prospective	FibroTest	F4 / 0.29	0.89 (0.04)	0.10 0.30 0.60 0.80	1.00 0.92 0.79 0.67	0.33 0.62 0.81 0.92
Callewaert, 2004	82	Prospective	Glyco Cirrho Test	F4 ** / 0.29	0.87 (0.04)	-0.2 0.1 0.4 0.6	1.00 0.79 0.21 0.17	0.12 0.88 0.95 1.00

* Number of patients. ** Compensated

Back to article page

Comparative Hepatology